Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene’s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis’ key drug Abraxane hit certain goals. “These structures are a great way for [...]
A Utah doctor is being sent to jail for his connection to an illegal online pharmacy that sold more than eight million weight-loss pills manufactured in Mexico. Dr James A Brinton was sentenced to three years in a federal penitentiary after he pleaded guilty to conspiracy to distribute phentermine and conspiracy to commit international money [...]
Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five largest drug classes by sales. But annual sales are only half the story. Which drug classes are booming, and which have plateaued–or even dropped? IMS Health has released top-line industry data revealing the 15 largest drug classes, and we’ve crunched the numbers to take a closer [...]
Eli Lilly (NYSE: LLY) is looking to its pipeline to fill the gaps left by a number of high-profile drugs coming off patent. In October 2011, blockbuster Zyprexa will fall to generic competition; additionally, about three-quarters of Lilly’s current revenue comes from eight drugs that will lose patent protection between now and 2017. ”We have the challenge [...]
Nigeria is fast-tracking mobile authentication services in its fight against drug counterfeiters. Manufacturers will bear the brunt of the cost, at least initially. The costal country of 150 million is at the forefront of African anti-counterfeiting efforts, thanks largely to a rampant supply of malaria drug fakes. In mid-May, the nonprofit Pedigree Network and computer [...]
Over the next five years, the market for biosimilars will swell to $10 billion, but only a handful of players with deep pockets and world-class R&D facilities will be able to play. And that means that most small- and medium-size drug developers will never have a chance of leaping into the new market for follow-on [...]
Hold onto your hats: The global market for contract manufacturing is headed for speedy growth over the next few years. According to a new report from RNCOS, pharmaceutical contract manufacturing is poised to grow about 12 percent per year from 2010 to 2012. Cost is one of the reasons, of course.
Gulf Coast native Kindra Arnesen is so anxious about the effects of the Gulf of Mexico oil spill she is packing up her family and leaving town. “Stress? Dude my clothes are falling off me (because of weight loss). The level of stress here is tremendous. My husband has aged 10 years in two [...]
The clock is ticking on Pfizer’s final, 18-month countdown on its $11.5 billion Lipitor franchise, but analysts are growing increasing fretful about the pharma giant’s ability to find new drugs to fill the looming revenue chasm. Pfizer had to admit that it suspended a slate of osteoarthritis trials after its highly touted pain drug tanezumab–billed as [...]
While the overall economy may be flagging, Maryland says that its biotech industry is booming. And the governor wants to keep the momentum going with a few new industry incentives. Gov. Martin O’Malley told reporters that the biotech industry added more than a thousand jobs in the last three months; that’s 10 percent of the [...]
You are currently browsing the weblog archives for 'generic drugs' tag.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Biotech Trading Signals Pharma News Biotech News